JP2018526375A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526375A5
JP2018526375A5 JP2018511130A JP2018511130A JP2018526375A5 JP 2018526375 A5 JP2018526375 A5 JP 2018526375A5 JP 2018511130 A JP2018511130 A JP 2018511130A JP 2018511130 A JP2018511130 A JP 2018511130A JP 2018526375 A5 JP2018526375 A5 JP 2018526375A5
Authority
JP
Japan
Prior art keywords
cancer
mutation
pharmaceutical combination
combination according
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018511130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/055049 external-priority patent/WO2017037578A2/en
Publication of JP2018526375A publication Critical patent/JP2018526375A/ja
Publication of JP2018526375A5 publication Critical patent/JP2018526375A5/ja
Pending legal-status Critical Current

Links

JP2018511130A 2015-08-28 2016-08-24 組み合わせ療法 Pending JP2018526375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562211014P 2015-08-28 2015-08-28
US62/211,014 2015-08-28
PCT/IB2016/055049 WO2017037578A2 (en) 2015-08-28 2016-08-24 Combination therapy

Publications (2)

Publication Number Publication Date
JP2018526375A JP2018526375A (ja) 2018-09-13
JP2018526375A5 true JP2018526375A5 (cg-RX-API-DMAC7.html) 2019-10-03

Family

ID=56896741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511130A Pending JP2018526375A (ja) 2015-08-28 2016-08-24 組み合わせ療法

Country Status (5)

Country Link
US (1) US20180256557A1 (cg-RX-API-DMAC7.html)
EP (1) EP3380097A2 (cg-RX-API-DMAC7.html)
JP (1) JP2018526375A (cg-RX-API-DMAC7.html)
CN (1) CN107921026A (cg-RX-API-DMAC7.html)
WO (1) WO2017037578A2 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20130072507A1 (en) * 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
AU2013299841B8 (en) * 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
EP2959014B1 (en) * 2013-02-25 2019-11-13 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant

Similar Documents

Publication Publication Date Title
JP2017526662A5 (cg-RX-API-DMAC7.html)
JP2014193925A5 (cg-RX-API-DMAC7.html)
IL302093A (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
JP2019527202A5 (cg-RX-API-DMAC7.html)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2018526376A5 (cg-RX-API-DMAC7.html)
JP2009514870A5 (cg-RX-API-DMAC7.html)
JP2014510729A5 (cg-RX-API-DMAC7.html)
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
JP2013507415A5 (cg-RX-API-DMAC7.html)
RU2017115771A (ru) 17a,21-диэфиры кортексолона для применения в лечении опухолей
JP2017528475A5 (cg-RX-API-DMAC7.html)
JP2016531871A5 (cg-RX-API-DMAC7.html)
JP2016525097A5 (cg-RX-API-DMAC7.html)
JO3434B1 (ar) مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
EA201691342A1 (ru) Пиразолоновые соединения и их применение
JP2019511550A5 (cg-RX-API-DMAC7.html)
JP2019533651A5 (cg-RX-API-DMAC7.html)
RU2018134336A (ru) Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина
JP2018503697A5 (cg-RX-API-DMAC7.html)
JP2019534865A5 (cg-RX-API-DMAC7.html)
JP2014507412A5 (cg-RX-API-DMAC7.html)
JP2016514727A5 (cg-RX-API-DMAC7.html)
JP2018514557A5 (cg-RX-API-DMAC7.html)